Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment
Open Access
- 1 March 2011
- journal article
- Published by Elsevier in Brain Research
- Vol. 1380, 106-119
- https://doi.org/10.1016/j.brainres.2010.11.032
Abstract
No abstract availableKeywords
Funding Information
- FRAXA Research Foundation
- Autism Speaks
- Albert Einstein College of Medicine
- NIH-NINDS
- NIGMS
This publication has 81 references indexed in Scilit:
- Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndromeBiochemical Pharmacology, 2010
- Age-dependent cognitive impairment in a Drosophila Fragile X model and its pharmacological rescueBiogerontology, 2009
- Reversing Neurodevelopmental Disorders in AdultsNeuron, 2008
- Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potentialNeuropharmacology, 2008
- Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and FunctionNeuron, 2008
- Autism and Brain DevelopmentCell, 2008
- Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO miceNeurobiology of Disease, 2008
- Correction of Fragile X Syndrome in MiceNeuron, 2007
- Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEPNeuropharmacology, 2005
- Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X SyndromeNeuron, 2005